Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaceutical contract research organization Frontage Laboratories has received an approval to expand the scope of its US Drug Enforcement Agency (DEA) license to include formulation development and manufacture of GMP clinical trial materials (CTM).
Subscribe to our email newsletter
The approval enables pharma firms that develop pain therapeutics to rely on Frontage for controlled-substance product development support services.
Frontage has upgraded its units, security and personnel procedures at both of its Exton, Pennsylvania sites to gain the expanded DEA license to conduct formulation development and GMP clinical trial material manufacturing.
The company, which offers a full spectrum of integrated services, has been supporting firms developing DEA Schedules I – V controlled substances.